WOCKPHARMA.NS Profit & Loss
Wockhardt Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:46
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹26.51 Bn | ₹27.98 Bn | ₹30.12 Bn | ₹33.73 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹1.22 Bn | ₹0.83 Bn | ₹0.62 Bn | ₹1.11 Bn | OtherIncome |
| Total Income | ₹27.73 Bn | ₹28.81 Bn | ₹30.74 Bn | ₹34.84 Bn | Income |
| Cost of Materials Consumed | ₹5.18 Bn | ₹6.20 Bn | ₹6.12 Bn | ₹6.74 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹5.09 Bn | ₹5.59 Bn | ₹5.73 Bn | ₹5.86 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹0.84 Bn | ₹-0.14 Bn | ₹-0.53 Bn | ₹-1.28 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹6.37 Bn | ₹6.29 Bn | ₹6.51 Bn | ₹7.25 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹3.02 Bn | ₹3.05 Bn | ₹2.54 Bn | ₹2.13 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹2.51 Bn | ₹2.23 Bn | ₹2.17 Bn | ₹2.27 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹8.02 Bn | ₹9.65 Bn | ₹8.36 Bn | ₹8.64 Bn | OtherExpenses |
| Total Expenses | ₹31.03 Bn | ₹32.87 Bn | ₹30.90 Bn | ₹31.61 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹-3.30 Bn | ₹-4.06 Bn | ₹-0.16 Bn | ₹3.23 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-2.94 Bn | ₹-0.14 Bn | ₹0.00 Bn | ₹-0.85 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹-6.24 Bn | ₹-4.20 Bn | ₹-0.16 Bn | ₹2.38 Bn | ProfitBeforeTax |
| Tax Expense | ₹-0.03 Bn | ₹0.52 Bn | ₹0.41 Bn | ₹0.39 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹-6.21 Bn | ₹-4.72 Bn | ₹-0.57 Bn | ₹1.99 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹-5.59 Bn | ₹-4.63 Bn | ₹-0.47 Bn | ₹2.13 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹-38.79 | ₹-32.05 | ₹-3.02 | ₹13.12 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹-38.79 | ₹-32.05 | ₹-3.02 | ₹13.10 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from WOCKPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).